OTCMKTS:ENZN Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free ENZN Stock Alerts $0.09 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$0.09▼$0.0950-Day Range$0.06▼$0.0952-Week Range$0.06▼$0.22Volume30,300 shsAverage Volume8,026 shsMarket CapitalizationN/AP/E Ratio8.68Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsSEC FilingsShort Interest Get Enzon Pharmaceuticals alerts: Email Address Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN)Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.Read More ENZN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENZN Stock News HeadlinesNovember 8, 2023 | morningstar.comEnzon Pharmaceuticals Inc ENZNOctober 25, 2023 | finance.yahoo.comOKYO Pharma Limited (OK10.F)May 12, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.July 30, 2023 | nasdaq.comRegeneron Pharmaceuticals, Inc. Common Stock (REGN)March 26, 2023 | thestreet.comEnzon Stock Hits New 52-Week Low (ENZN)March 20, 2023 | investing.comIbnsina Pharma Co (ISPH)February 26, 2023 | time.comBig Pharma’s Patent Abuses Are Fueling the Drug Pricing CrisisJuly 15, 2022 | morningstar.comEnzon Pharmaceuticals Inc - Stock Operating Performance ENZNMay 12, 2024 | Crypto Swap Profits (Ad)He Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.July 2, 2022 | finance.yahoo.comEnzon Pharmaceuticals, Inc. (ENZN)See More Headlines Receive ENZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today5/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolOTCMKTS:ENZN Previous SymbolNASDAQ:ENZN CUSIP29390410 CIK727510 Webwww.enzon.com Phone(732) 980-4500Fax732-980-4585EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio8.68 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.37 million Net MarginsN/A Pretax Margin3,573.08% Return on Equity46.47% Return on Assets2.92% Debt Debt-to-Equity RatioN/A Current Ratio27.62 Quick Ratio27.62 Sales & Book Value Annual Sales$30,000.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.39 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Richard L. Feinstein (Age 81)CEO, CFO & Company Secretary Comp: $209.45kKey CompetitorsAdvanced Life SciencesOTCMKTS:ADLSAVAX TechnologiesOTCMKTS:AVXTClarus TherapeuticsOTCMKTS:CRXTQGene BiotherapeuticsOTCMKTS:CRXMGenocea BiosciencesNASDAQ:GNCAQView All Competitors ENZN Stock Analysis - Frequently Asked Questions How have ENZN shares performed in 2024? Enzon Pharmaceuticals' stock was trading at $0.0936 at the beginning of 2024. Since then, ENZN shares have decreased by 7.3% and is now trading at $0.0868. View the best growth stocks for 2024 here. Are investors shorting Enzon Pharmaceuticals? Enzon Pharmaceuticals saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 1,600 shares, a decline of 87.6% from the April 15th total of 12,900 shares. Based on an average daily volume of 1,100 shares, the short-interest ratio is currently 1.5 days. View Enzon Pharmaceuticals' Short Interest. How were Enzon Pharmaceuticals' earnings last quarter? Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) released its earnings results on Wednesday, March, 20th. The biotechnology company reported $0.01 EPS for the quarter. What other stocks do shareholders of Enzon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enzon Pharmaceuticals investors own include Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Golar LNG Partners (GMLP), Washington Prime Group (WPG), DHT (DHT), Hallador Energy (HNRG) and Medical Marijuana (MJNA). How do I buy shares of Enzon Pharmaceuticals? Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ENZN) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enzon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
